A gastrointestinal stromal tumor (GIST) masquerading as an ovarian mass
- PDF / 640,262 Bytes
- 3 Pages / 610 x 792 pts Page_size
- 2 Downloads / 198 Views
Open Access
Case report
A gastrointestinal stromal tumor (GIST) masquerading as an ovarian mass Giorgio Carlomagno*1 and Pasquale Beneduce2 Address: 1Università di Roma "La Sapienza" – Corso di Laurea in Ostetricia, U. O. C. Ginecologia e Ostetricia – A.O. "G. Rummo", Benevento, Italy and 2U. O. C. Chirurgia d'Urgenza – A. O. 'U Rummo", Benevento, Italy Email: Giorgio Carlomagno* - [email protected]; Pasquale Beneduce - [email protected] * Corresponding author
Published: 13 May 2004 World Journal of Surgical Oncology 2004, 2:15
Received: 18 February 2004 Accepted: 13 May 2004
This article is available from: http://www.wjso.com/content/2/1/15 © 2004 Carlomagno and Beneduce; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
Gastrointestinal stromal tumorsGISTovarian neoplasm
Abstract Background: Malignant gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors originating in the wall of the gastrointestinal tract. Myogenic gastrointestinal stromal tumor, a distinctive morphologic variant is characterized by an unusually prominent myxoid stromal background. Case presentation: We report a case of myxoid variant of GIST in a 42 years old woman presenting as an epigastric mass associated to an ovarian cyst and elevated CA-125. Histologically, the lesions was composed of a proliferation of spindle cells in an abundant myxoid stroma, without evidence of atypia or anaplasia. Immunohistochemical stains showed strong positive staining with muscle actin, positive staining with CD34 and weak positive staining with CD117, while showed negative for S-100. Conclusion: At surgery every effort should be made to identify the origin of the tumor. A complete surgical removal of the tumor should be obtained, as this is the only established treatment that offers long term survival.
Background Gastrointestinal stromal tumors (GIST) are rare tumors that may arise anywhere in the tubular gastrointestinal tract, but stomach is the most common site of localization. Surgery is the main stay of treatment and complete resection is achieved in most of cases [1]. The 5 year overall survival ranges from 21% to 88% in different series, depending from risk grading and completeness of surgical resection [1-4]. In light of the tendency of these tumors to pursue an indolent clinical course with a significant risk of late relapse, a brisk follow-up is advocated for all patients [5]. Imatinib mesylate is proposed as therapy for high risk
GISTs after surgery [6]. A distinctive morphologic variant of gastrointestinal stromal tumor has been described, characterized by a prominent myxoid stromal background reminiscent of a neural neoplasm but lacking the immunohistochemical or ultrastructural features of peripheral nerve sheath or ganglionic differentiation. This variant is more frequent in women and mostly occurs in the stomach. These le
Data Loading...
